Detalhe da pesquisa
1.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 138(26): 2753-2767, 2021 12 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34724563
2.
Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile.
Ann Hematol
; 102(11): 3015-3023, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37535147
3.
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
Am J Hematol
; 98(12): 1847-1855, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37671649
4.
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.
Int J Mol Sci
; 24(4)2023 Feb 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36834477
5.
Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial.
Haematologica
; 107(12): 2823-2833, 2022 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35295076
6.
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Ann Hematol
; 101(5): 963-978, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35201417
7.
Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia.
Mycoses
; 65(2): 233-238, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34883533
8.
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.
Blood
; 134(12): 935-945, 2019 09 19.
Artigo
Inglês
| MEDLINE | ID: mdl-31395600
9.
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial.
Future Oncol
; 17(29): 3787-3796, 2021 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-34254530
10.
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
Br J Haematol
; 190(6): 891-900, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32239670
11.
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 131(12): 1275-1291, 2018 03 22.
Artigo
Inglês
| MEDLINE | ID: mdl-29330221
12.
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment.
Hematol Oncol
; 38(2): 189-196, 2020 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-31891213
13.
AML: making residual disease more measurable.
Blood
; 140(5): 415-417, 2022 08 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35925646
14.
Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study.
Ann Hematol
; 98(5): 1083-1093, 2019 May.
Artigo
Inglês
| MEDLINE | ID: mdl-30868306
15.
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
Hematol Oncol
; 36(1): 285-290, 2018 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-28512865
16.
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
Ann Hematol
; 97(10): 1767-1774, 2018 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-29947973
17.
Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?
Curr Opin Hematol
; 24(2): 132-138, 2017 03.
Artigo
Inglês
| MEDLINE | ID: mdl-27930388
18.
Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia.
Haematologica
; 107(11): 2752-2755, 2022 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35924584
19.
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.
Haematologica
; 102(5): 865-873, 2017 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28126965
20.
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Ann Hematol
; 96(3): 387-391, 2017 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-27889820